How Will Resonance Health’s New Mandurah Site Transform Clinical Trials?

Expansion of TrialsWest Network

Resonance Health Limited (ASX – RHT) has announced a significant step forward in its clinical trials business with the planned opening of a third TrialsWest site in Mandurah, Western Australia, scheduled for August 2025. This new site will complement the existing locations in Perth’s Spearwood suburb and another site, substantially increasing the capacity to recruit participants for ongoing and future pharmaceutical clinical trials.

Strategic Location in a Growing City

Mandurah, located approximately 72 kilometers south of Perth, is one of Australia’s fastest-growing cities, with a population nearing 105,000 and a remarkable 91% growth over the past two decades. This demographic expansion offers a fertile ground for clinical trial recruitment, providing TrialsWest with access to a broader and more diverse participant pool. The city’s infrastructure, including good transport links and affordable site establishment costs, aligns well with Resonance Health’s strategy to expand in accessible, densely populated areas.

Growth Strategy and Market Positioning

The addition of the Mandurah site is a clear continuation of the growth trajectory outlined by Resonance Health following its acquisition of TrialsWest. The company aims to build a multi-site clinical trial platform that services a diverse range of pharmaceutical customers and trials over several years. This expansion not only supports the current major pharma clinical trials managed by the group but also opens opportunities to increase recruitment for other existing trials, enhancing the overall service offering.

Broader Implications for Resonance Health

Beyond TrialsWest, Resonance Health is known for its advanced MRI-based medical imaging technologies, including AI-driven devices for liver and cardiac assessments. The growth of its clinical trial management arm complements its core technology offerings by providing a robust infrastructure for drug development and disease management studies. CEO Andrew Harrison expressed optimism about the expansion, highlighting the significant opportunity TrialsWest represents as a platform for future growth.

Looking Ahead

Resonance Health’s strategy includes targeting further new clinical trial sites and complementary acquisitions, suggesting that the Mandurah site is just the beginning of a broader expansion plan. Investors and industry watchers will be keen to monitor how this increased capacity translates into participant recruitment success and financial performance in upcoming reporting periods.